175 related articles for article (PubMed ID: 22040065)
1. Borrowing strength with nonexchangeable priors over subpopulations.
Leon-Novelo LG; Bekele BN; Müller P; Quintana F; Wathen K
Biometrics; 2012 Jun; 68(2):550-8. PubMed ID: 22040065
[TBL] [Abstract][Full Text] [Related]
2. Bayesian optimal design for phase II screening trials.
Ding M; Rosner GL; Müller P
Biometrics; 2008 Sep; 64(3):886-894. PubMed ID: 18162113
[TBL] [Abstract][Full Text] [Related]
3. Quantification of prior impact in terms of effective current sample size.
Wiesenfarth M; Calderazzo S
Biometrics; 2020 Mar; 76(1):326-336. PubMed ID: 31364156
[TBL] [Abstract][Full Text] [Related]
4. Robust exchangeability designs for early phase clinical trials with multiple strata.
Neuenschwander B; Wandel S; Roychoudhury S; Bailey S
Pharm Stat; 2016; 15(2):123-34. PubMed ID: 26685103
[TBL] [Abstract][Full Text] [Related]
5. Bayesian hierarchical classification and information sharing for clinical trials with subgroups and binary outcomes.
Chen N; Lee JJ
Biom J; 2019 Sep; 61(5):1219-1231. PubMed ID: 30506747
[TBL] [Abstract][Full Text] [Related]
6. A Bayesian basket trial design that borrows information across strata based on the similarity between the posterior distributions of the response probability.
Fujikawa K; Teramukai S; Yokota I; Daimon T
Biom J; 2020 Mar; 62(2):330-338. PubMed ID: 31608505
[TBL] [Abstract][Full Text] [Related]
7. Bayesian basket trial design with exchangeability monitoring.
Hobbs BP; Landin R
Stat Med; 2018 Nov; 37(25):3557-3572. PubMed ID: 29984488
[TBL] [Abstract][Full Text] [Related]
8. Bayesian hierarchical modeling of patient subpopulations: efficient designs of Phase II oncology clinical trials.
Berry SM; Broglio KR; Groshen S; Berry DA
Clin Trials; 2013 Oct; 10(5):720-34. PubMed ID: 23983156
[TBL] [Abstract][Full Text] [Related]
9. Bayesian cluster hierarchical model for subgroup borrowing in the design and analysis of basket trials with binary endpoints.
Chen N; Lee JJ
Stat Methods Med Res; 2020 Sep; 29(9):2717-2732. PubMed ID: 32178585
[TBL] [Abstract][Full Text] [Related]
10. Bayesian hierarchical models for adaptive basket trial designs.
Chen C; Hsiao CF
Pharm Stat; 2023; 22(3):531-546. PubMed ID: 36625301
[TBL] [Abstract][Full Text] [Related]
11. Subgroup-specific dose finding for phase I-II trials using Bayesian clustering.
Curtis A; Smith B; Chapple AG
Stat Med; 2022 Jul; 41(16):3164-3179. PubMed ID: 35429178
[TBL] [Abstract][Full Text] [Related]
12. A Bayesian adaptive design for dual-agent phase I-II oncology trials integrating efficacy data across stages.
Jiménez JL; Zheng H
Biom J; 2023 Oct; 65(7):e2200288. PubMed ID: 37199700
[TBL] [Abstract][Full Text] [Related]
13. Bayesian semiparametric meta-analytic-predictive prior for historical control borrowing in clinical trials.
Hupf B; Bunn V; Lin J; Dong C
Stat Med; 2021 Jun; 40(14):3385-3399. PubMed ID: 33851441
[TBL] [Abstract][Full Text] [Related]
14. Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes.
Thall PF; Wathen JK; Bekele BN; Champlin RE; Baker LH; Benjamin RS
Stat Med; 2003 Mar; 22(5):763-80. PubMed ID: 12587104
[TBL] [Abstract][Full Text] [Related]
15. Bayesian design of noninferiority trials for medical devices using historical data.
Chen MH; Ibrahim JG; Lam P; Yu A; Zhang Y
Biometrics; 2011 Sep; 67(3):1163-70. PubMed ID: 21361889
[TBL] [Abstract][Full Text] [Related]
16. Robust meta-analytic-predictive priors in clinical trials with historical control information.
Schmidli H; Gsteiger S; Roychoudhury S; O'Hagan A; Spiegelhalter D; Neuenschwander B
Biometrics; 2014 Dec; 70(4):1023-32. PubMed ID: 25355546
[TBL] [Abstract][Full Text] [Related]
17. Leveraging historical data into oncology development programs: Two case studies of phase 2 Bayesian augmented control trial designs.
Smith CL; Thomas Z; Enas N; Thorn K; Lahn M; Benhadji K; Cleverly A
Pharm Stat; 2020 May; 19(3):276-290. PubMed ID: 31903699
[TBL] [Abstract][Full Text] [Related]
18. Practical guidelines for adaptive seamless phase II/III clinical trials that use Bayesian methods.
Kimani PK; Glimm E; Maurer W; Hutton JL; Stallard N
Stat Med; 2012 Aug; 31(19):2068-85. PubMed ID: 22437262
[TBL] [Abstract][Full Text] [Related]
19. Bayesian meta-experimental design: evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes.
Ibrahim JG; Chen MH; Xia HA; Liu T
Biometrics; 2012 Jun; 68(2):578-86. PubMed ID: 21955084
[TBL] [Abstract][Full Text] [Related]
20. A nonparametric Bayesian basket trial design.
Xu Y; Müller P; Tsimberidou AM; Berry D
Biom J; 2019 Sep; 61(5):1160-1174. PubMed ID: 29808479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
